乳腺癌患者血清脂联素检测的临床意义

The clinical significance of determination of adiponectin for the patients of breast cancer

目的:探讨乳腺癌患者血清脂联素含量的变化及其临床意义。方法:选择病理确诊的乳腺癌住院患者77例(转移者53例、未转移者24例)、对照组36例,术前抽取空腹静脉血并取血清,EL ISA法测定血清脂联素含量。结果:对照组血清脂联素含量7.29±2.06mg/L,乳腺癌未转移组血清脂联素含量4.51±1.98mg/L,乳腺癌转移组血清脂联素含量2.70±1.50mg/L,其含量逐渐下降(P<0.01)。乳腺癌患者TNM分期Ⅱ、Ⅲ、Ⅳ期血清脂联素含量依次为2.81±1.65mg/L,2.66±1.58mg/L,2.32±1.41mg/L,均低于Ⅰ期血清脂联素含量4.46±2.04mg/L(P<0.01),而Ⅱ、Ⅲ、Ⅳ期之间无显著性差异(P>0.05)。结论:乳腺癌患者血清脂联素含量降低,脂联素含量的降低程度在预测乳腺癌转移和预后方面具有指导意义。

Objective： To explore the clinical significance of determination of adiponectin for the patients of breast cancer . Methods： According to metastasis of carcinoma or not , 77 patients of breast cancer who were diagnosed by pathology were divided into the metastasis group with 53 patients and the no-metastasis group with 24 patients, 36 normal women were control group . The fasting venous blood was taken from all subjects. And Serum adiponectin concentrations was determined with enzyme linked immunosorbent assay（ELISA）. Results： Serum adiponectin concentrations in the metastasis group （2. 70 ± 1. 50mg/L） were lower than those in the no-metastasis group （4. 51 ± 1. 98mg/L）（P〈0.01）, which were lower in the control group（7.29±2.06mg/L）（P〈0. 01）. And Serum adiponectin in patients of TNM （2. 81± 1.65mg/L）, Ⅱ （2. 66±1. 58 mg/L） and Ⅳ （2. 32±1.4ling/L） stage of breast cancer were lower than that in patients of TNM Ⅰ （4.46±2.04mg/L）stage, but adiponectin concentrations showed not significant difference in patients of TNM Ⅱ, Ⅲ and Ⅳ stage （P〉 0. 05）. Conclusion： Serum adiponectin concentrations in patients of breast cancer were lower than in normal women, and the serum adiponectin stepping down may predict metastasis and prognosis of breast cancer .